36 related articles for article (PubMed ID: 35996877)
1. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
Watanabe A; Kotsuma M
Drug Metab Pharmacokinet; 2024 Apr; 55():101000. PubMed ID: 38458122
[TBL] [Abstract][Full Text] [Related]
3. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.
Cleary Y; Kletzl H; Grimsey P; Heinig K; Ogungbenro K; Silber Baumann HE; Frey N; Aarons L; Galetin A; Gertz M
Clin Pharmacokinet; 2023 Jun; 62(6):891-904. PubMed ID: 37148485
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
Guo Y; Xue H; Hu N; Liu Y; Sun H; Yu D; Qin L; Shi G; Wang F; Xin L; Sun W; Zhang F; Song X; Li S; Wei Q; Guo Y; Li Y; Liu X; Chen S; Zhang T; Wu Y; Su D; Zhu Y; Xu A; Xu H; Yang S; Zheng Z; Liu J; Yang X; Yuan X; Hong Y; Sun X; Guo Y; Zhou C; Liu X; Wang L; Wang Z
J Med Chem; 2024 May; ():. PubMed ID: 38695063
[TBL] [Abstract][Full Text] [Related]
5. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
Rowland Yeo K; Gil Bergland E; Chen Y
Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38686708
[TBL] [Abstract][Full Text] [Related]
6. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
Gong JQX; Suleiman AA; Menon R; Deng R; Mensing S; Salem AH
J Clin Pharmacol; 2023 Aug; 63(8):950-960. PubMed ID: 37055934
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia.
De Gregori S; Gelli E; Capone M; Gambini G; Roncoroni E; Rossi M; Tobar Cabrera CP; Martini G; Calabretta L; Arcaini L; Albertini R; Zappasodi P
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376128
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients.
Badawi M; Menon R; Place AE; Palenski T; Sunkersett G; Arrendale R; Deng R; Federico SM; Cooper TM; Salem AH
J Cancer; 2023; 14(7):1151-1156. PubMed ID: 37215448
[TBL] [Abstract][Full Text] [Related]
9. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.
Wang X; Chen F; Guo N; Gu Z; Lin H; Xiang X; Shi Y; Han B
Cancer Chemother Pharmacol; 2023 Oct; 92(4):253-270. PubMed ID: 37466731
[TBL] [Abstract][Full Text] [Related]
10. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
[TBL] [Abstract][Full Text] [Related]
13. Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
Mukherjee D; Brackman DJ; Suleiman AA; Zha J; Menon RM; Salem AH
J Clin Pharmacol; 2023 Jan; 63(1):119-125. PubMed ID: 35996877
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
15. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]